1. Melatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model
- Author
-
Ulkan Kilic, Burak Yulug, Seyda Cankaya, Ertugrul Kilic, Muzaffer Beyza Ozansoy, Sule Goktekin, Mehmet Ozansoy, ALKÜ, and 0-belirlenecek
- Subjects
SH-SY5Y ,Amyloid beta ,tau Proteins ,Alzheimer's Disease ,Exosomes ,Exosome ,Melatonin ,03 medical and health sciences ,Pineal gland ,0302 clinical medicine ,Cell Line, Tumor ,Physiology (medical) ,Humans ,Medicine ,Viability assay ,Neurons ,Amyloid beta-Peptides ,biology ,business.industry ,Cell growth ,Amyloid-Beta ,General Medicine ,Alzheimer's disease ,Microvesicles ,Cell biology ,medicine.anatomical_structure ,Neurology ,030220 oncology & carcinogenesis ,biology.protein ,Surgery ,Neurology (clinical) ,Amyloid-beta ,Tau ,business ,hormones, hormone substitutes, and hormone antagonists ,030217 neurology & neurosurgery ,medicine.drug - Abstract
PubMed: 32061493 Background: Recent studies have been revealed that oxidative damage is the main cause of aging and age-related neurodegenerative diseases like Alzheimer's disease (AD). Melatonin is secreted from the pineal gland and its secretion has been found to be altered in AD. In the last decade the role of exosomes in spreading toxic proteins and inducing the propagation of diseases like AD has been discussed. However, it is not known how melatonin affects the amount of exosomes released from the cells and the content of the exosomes. Objective: Herein, we investigated the possible role of melatonin treatment in the releasing of exosomes and exosomal tau content in an in vitro A? toxicity model. Method: SH-SY5Y cell line was used. The optimum concentration of A? was determined by cell viability and cell proliferation tests. Melatonin (100 µM) was applied before and after A? application. Total exosomes isolated from cell culture media were immunoprecipitated. The amount of released exosomes and their tau content were analyzed by Western blots. Results: Our data demonstrated for the first time that melatonin treatment clearly affected the amount of released exosomes. It would decrease the amyloid beta load and toxicity by inhibiting exosome release. We also demonstated that melatonin also affected the level of tau carried by exosomes depending on whether melatonin was applied before or after A? application. Conclusion: It is considered that the effect of melatonin in the release of exosomes and exosomal tau content would contribute the development of therapeutic strategies in AD and related disorders. © 2019 Elsevier Ltd
- Published
- 2020